Loading…
← CockpitCompetitor Analysis › 300702.SZ Zhejiang Tianyu Pharmaceutical Co. Ltd. Class AOpen in the cockpit ↗

Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A300702.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Taizhou maker of generic active ingredients, best known for sartan blood-pressure drugs, plus contract (CDMO) work and finished formulations.

Momentum leader 81
Mkt cap
$1.02B
US dollars, full cap
Free float
60%
of shares outstanding
$/day
$6.76M
20-day average traded
Fwd P/E
21.4×
forward earnings
ROIC−WACC
+0.5 pp
WACC 5.6%
Hurdle
+1 pp
Req g minus delivered
Next earnings
149 days
16 Apr 2027
Close · CNYCN¥19.80
1D-3.7%
1W-5.3%
1M-5.0%
3M-12.4%
6M+1.2%
YTD-16.1%
1Y-21.1%
ATR %3.9%
52w lowhigh28.8% off high

What Zhejiang Tianyu Pharmaceutical does

Taizhou maker of generic active ingredients, best known for sartan blood-pressure drugs, plus contract (CDMO) work and finished formulations.

Earns most of its income selling sartan blood-pressure ingredients and intermediates to generic drugmakers, with international buyers such as Teva and Sandoz taking much of it. It is adding contract development and manufacturing for other drug companies and its own finished tablets to lessen reliance on bulk ingredients.

Products and services

  • Sartan APIs and intermediates (valsartan, telmisartan)
  • Other generic APIs and intermediates
  • CDMO APIs and intermediates
  • Finished formulations

Customers

  • Generic drugmakers worldwide (Teva, Polpharma, San
  • Innovator drug companies (CDMO)
  • Domestic drug companies

Where it sits in the supply chain

  • Pharmaceuticals
  • Active ingredients and intermediates
  • Sartan APIs

What could go right

  • CDMO and new generic API launches
  • Finished-formulation business

What could go wrong

  • API price competition
  • Nitrosamine and environmental compliance

Moat: narrow (regulatory licence, process know-how). European CEP and other regulatory filings plus process know-how; ingredient prices remain competitive.

Headquarters: Taizhou, China · Founded: 2003 · Employees: 4,686

Named competitors

Zhejiang Tianyu Pharmaceutical at a glance

Size Zhejiang Tianyu Pharmaceutical (300702.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.02B, the 2128th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥19.80 on 18 Nov 2026.

Performance Over six months the shares gained 1.2%, against -11.5% for the median peer and -20.0% for the China market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 27.2% over the last twelve months (peer median +5.9%); the operating margin is 4.0% (peer median 10.9%).

Valuation It trades at 21.4× forward earnings against a peer median of 18.3× (7th most expensive of 15).

Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.5 points above its cost of capital (5.6% WACC).

Next results Next results expected around 16 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026300702.SZ 103Peer median 91
Six months, rebased to 100: Zhejiang Tianyu Pharmaceutical against the median of its 20 peers (local-currency closes).

Zhejiang Tianyu Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.79BCN¥3.04BCN¥2.62BCN¥2.51BCN¥2.66B
Revenue growth—+16%+4%-6%—
Gross profitCN¥1.40BCN¥1.02BCN¥810MCN¥889MCN¥603M
EBITDAn/aCN¥559MCN¥444MCN¥453MCN¥176M
Net incomeCN¥69.3MCN¥140MCN¥55.9MCN¥27.4M-CN¥119M
Free cash flowCN¥506MCN¥116MCN¥176M-CN¥361M-CN¥575M
Capital expenditureCN¥337MCN¥358MCN¥169MCN¥317MCN¥527M
Total debtCN¥2.34BCN¥2.16BCN¥2.37BCN¥2.14BCN¥1.99B

Quarterly statements and history in the cockpit →

Zhejiang Tianyu Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%00065048873004976885134553688091605116688710002737SVRABSLN600789BLUEJETAARTIPHARM1952688382SPTXPGHL300702.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Zhejiang Tianyu Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%+200%0×20×40×60×00065048873004976885134553688710002737BSLN600557BLUEJET1952600129300702.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhejiang Tianyu Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-50%-25%0%+25%-50%0%0006503004976885134553605116688710002737BSLNBLUEJET688382300702.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Zhejiang Tianyu Pharmaceutical is the large dot.

Zhejiang Tianyu Pharmaceutical competitors and peer comparison

Head to head with its named competitors (300702.SZ vs 600521.SS vs AUROPHARMA.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Zhejiang Tianyu Pharmaceutical 300702.SZ$1.02B+1%+27%4%21.4×4.3%
Zhejiang Huahai Pharmaceutical 600521.SS$3.61B0%+10%12%20.1×6.4%
Aurobindo Pharma AUROPHARMA.NS$11.0B+19%+14%15%22.3×21.1%

How Zhejiang Tianyu Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhejiang Tianyu Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure300702.SZPeer medianRank in peer set
1-month return-5.0%-6.0%10th highest of 21
6-month return+1.2%-11.5%7th highest of 21
Distance from 52-week high-28.8%-32.4%9th highest of 21
Revenue growth (TTM)+27.2%+5.9%5th highest of 19
Operating margin4.0%10.9%6th lowest of 19
Forward P/E21.4×18.3×7th most expensive of 15
Growth the price implies (Req g, 7 yrs)4.3%2.5%7th most demanding of 14
Growth delivered (Del g)+3.5%+7.7%6th lowest of 14
Hurdle (Req g minus delivered)+0.8 pp-3.6 pp5th most demanding of 14
ROIC minus cost of capital+0.5 pp+0.1 pp9th highest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Zhejiang Tianyu Pharmaceutical 300702.SZChina$1.02B+1%+27%4%21.4×4.3%+3.5%
Renhe Pharmacy 000650.SZChina$1.01B-12%-7%14%16.9×-10.7%-7.0%
SAWAI 4887.TJapan$1.01B-18%+2%9%12.0×n/an/a
Jiangxi Fushine Pharmaceutical 300497.SZChina$1.02B-23%+103%24%9.9×7.5%-4.5%
Chengdu Easton Biopharmaceuticals 688513.SSChina$1.03B-33%-2%13%24.6×4.4%+7.7%
Towa Pharmaceutical 4553.TJapan$1.03B-10%+7%9%7.7×-0.3%+12.1%
Shanghai Yizhong Pharmaceutical 688091.SSChina$1.00B-49%+32%14%n/an/an/a
Aurisco Pharmaceutical 605116.SSChina$1.00B-23%+3%25%13.6×-2.0%+18.7%
Shanghai InnoStar Bio-tech 688710.SSChina$1,000M+17%+24%6%59.3×12.7%+19.4%
Sunflower Pharmaceutical 002737.SZChina$1.04B-11%+31%-7%4.7×-6.5%-7.7%
Savara SVRAUnited States$1.04B-7%n/an/an/an/an/a
Basilea Pharmaceutica BSLN.SWSwitzerland$1.04B+33%+5%24%10.5×-5.6%+12.7%
Jiangsu Kanion Pharmaceutical 600557.SSChina$989M-9%+8%7%19.8×2.3%+1.8%
Shandong Lukang Pharmaceutical 600789.SSChina$1.05B-18%-7%3%n/a2.5%+6.5%
Blue Jet Healthcare BLUEJET.NSIndia$1.05B+19%-7%28%30.6×40.8%+13.8%
Aarti Pharmalabs AARTIPHARM.NSIndia$984M+44%+13%18%n/an/an/a
Everest Medicines 1952.HKHong Kong$1.05B-20%+193%-5%23.2×n/an/a
InventisBio 688382.SSChina$982M-47%-61%-563%n/a6.5%-60.6%
Chongqing Taiji Industry (Group) 600129.SSChina$982M-20%-4%2%69.8×n/an/a
Seaport Therapeutics SPTXUnited States$980M+16%n/an/an/an/an/a
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%24.5×5.6%+9.3%

Questions

Who are Zhejiang Tianyu Pharmaceutical's main competitors?
Named competitors: Zhejiang Huahai Pharmaceutical (600521.SS), Aurobindo Pharma (AUROPHARMA.NS). The cockpit's measured peer set (industry) also includes Renhe Pharmacy (000650.SZ), SAWAI (4887.T), Jiangxi Fushine Pharmaceutical (300497.SZ), Chengdu Easton Biopharmaceuticals (688513.SS), Towa Pharmaceutical (4553.T), Shanghai Yizhong Pharmaceutical (688091.SS).
Is Zhejiang Tianyu Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 21.4× against a peer median of 18.3×, 7th most expensive of 15 in its peer set. For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Zhejiang Tianyu Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned +1.2% against -11.5% for the median peer; over one year -21.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.